Analysts Are Bullish on These Healthcare Stocks: PepGen Inc. (PEPG), GoodRx Holdings (GDRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG – Research Report) and GoodRx Holdings (GDRX – Research Report) with bullish sentiments.

PepGen Inc. (PEPG)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on PepGen Inc. yesterday and set a price target of $22.00. The company’s shares closed last Thursday at $5.64, close to its 52-week low of $4.26.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 4.8% and a 47.0% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Apellis Pharmaceuticals, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PepGen Inc. with a $24.00 average price target, which is a 358.9% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.

See today’s best-performing stocks on TipRanks >>

GoodRx Holdings (GDRX)

In a report released yesterday, Allen Lutz from Bank of America Securities maintained a Buy rating on GoodRx Holdings, with a price target of $9.50. The company’s shares closed last Thursday at $5.42.

According to TipRanks.com, Lutz is a 2-star analyst with an average return of -0.3% and a 56.4% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Walgreens Boots Alliance, and Patterson Companies.

Currently, the analyst consensus on GoodRx Holdings is a Moderate Buy with an average price target of $8.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PEPG:

• PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
• PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
• PepGen announces presentations of data on EDO platform
• PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
• PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference